These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32976551)

  • 1. Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease.
    Joseph L; Jean C; Manceau S; Chalas C; Arnaud C; Kamdem A; Pondarré C; Habibi A; Bernaudin F; Allali S; de Montalembert M; Boutonnat-Faucher B; Arlet JB; Koehl B; Cavazzana M; Ribeil JA; Lionnet F; Berthaut I; Brousse V
    Blood; 2021 Feb; 137(6):826-829. PubMed ID: 32976551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease.
    Grigg A
    Intern Med J; 2007 Mar; 37(3):190-2. PubMed ID: 17316339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints.
    Jones KM; Niaz MS; Brooks CM; Roberson SI; Aguinaga MP; Hills ER; Rice VM; Bourne P; Bruce D; Archibong AE
    Int J Environ Res Public Health; 2009 Mar; 6(3):1124-44. PubMed ID: 19440437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.
    DeBaun MR
    Expert Rev Hematol; 2014 Dec; 7(6):767-73. PubMed ID: 25242414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of hydroxyurea on fertility in male and female sickle cell disease patients. A systemic review and meta-analysis.
    Sewaralthahab S; Alsubki LA; Alhrabi MS; Alsultan A
    PLoS One; 2024; 19(6):e0304241. PubMed ID: 38848387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow transplantation or hydroxyurea for sickle cell anemia: long-term effects on semen variables and hormone profiles.
    Lukusa AK; Vermylen C; Vanabelle B; Curaba M; Brichard B; Chantrain C; Dupont S; Ferrant A; Wyns C
    Pediatr Hematol Oncol; 2009 Jun; 26(4):186-94. PubMed ID: 19437321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of Seminal Fluid Parameters and Fertility of Male Sickle Cell Disease Patients and Potential Impact of Hydroxyurea Treatment.
    Sahoo LK; Kullu BK; Patel S; Patel NK; Rout P; Purohit P; Meher S
    J Assoc Physicians India; 2017 Jun; 65(6):22-25. PubMed ID: 28782309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.
    Heitzer AM; Longoria J; Okhomina V; Wang WC; Raches D; Potter B; Jacola LM; Porter J; Schreiber JE; King AA; Kang G; Hankins JS
    Br J Haematol; 2021 Oct; 195(2):256-266. PubMed ID: 34272726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    Alvarez O; Yovetich NA; Scott JP; Owen W; Miller ST; Schultz W; Lockhart A; Aygun B; Flanagan J; Bonner M; Mueller BU; Ware RE;
    Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
    Patel DK; Mashon RS; Patel S; Das BS; Purohit P; Bishwal SC
    Hemoglobin; 2012; 36(5):409-20. PubMed ID: 22881992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
    Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five years of experience with hydroxyurea in children and young adults with sickle cell disease.
    Ferster A; Tahriri P; Vermylen C; Sturbois G; Corazza F; Fondu P; Devalck C; Dresse MF; Feremans W; Hunninck K; Toppet M; Philippet P; Van Geet C; Sariban E
    Blood; 2001 Jun; 97(11):3628-32. PubMed ID: 11369660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment.
    Berthaut I; Bachir D; Kotti S; Chalas C; Stankovic K; Eustache F; Ravel C; Habibi A; Brailly-Tabard S; Lévy-Dutel L; Bleibtreu A; Simon T; Galactéros F; Lionnet F; Mandelbaum J
    Blood; 2017 Nov; 130(21):2354-2356. PubMed ID: 28972009
    [No Abstract]   [Full Text] [Related]  

  • 16. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
    Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
    Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
    Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y
    Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
    Voskaridou E; Christoulas D; Bilalis A; Plata E; Varvagiannis K; Stamatopoulos G; Sinopoulou K; Balassopoulou A; Loukopoulos D; Terpos E
    Blood; 2010 Mar; 115(12):2354-63. PubMed ID: 19903897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
    Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
    Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective.
    Nnebe-Agumadu U; Adebayo I; Erigbuem I; James E; Kumode E; Nnodu O; Adekile A
    Pediatr Blood Cancer; 2021 Jun; 68(6):e28969. PubMed ID: 33788390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.